精品视频一区二区,91狠狠,欧美人成片免费观看视频

Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Filing After Trial Misses Survival Goal Biotech Merck Daiichi Sankyo Merck and Daiichi Sankyo have withdrawn their FDA application for patritumab deruxtecan after a Phase III trial failed to show significant overall survival benefits in EGFR-mutated NSCLC patients, citing regulatory discussions.
ASCO 2025 Colorectal Cancer Highlights: Plenary & Oral Sessions, Breakthrough Treatments & Studies ASCO Market Trend Cancer Discover the latest breakthroughs in colorectal cancer at ASCO 2025, featuring key plenary and oral presentations on innovative treatments like ATOMIC, BREAKWATER, ANCHOR, and KRAS G12C inhibitors. Stay ahead in oncology research.
Trump's Pharma Tariffs & Pricing Reforms: S&P Warns of Generic Sector Risks Trump Market Trend S&P Global reports that major pharma companies can withstand Trump’s proposed drug tariffs and MFN pricing, but warns that generic manufacturers may face serious risks from cost pressures and supply chain disruptions.
2025 ASCO: Major Breakthroughs in Gastric Cancer Treatment: Latest Advances Preview ASCO Market Trend Cancer Discover the latest breakthroughs in gastric cancer treatment from the 2025 ASCO Annual Meeting, including immunotherapy, targeted therapies, and CAR-T advances improving survival and hope for patients worldwide.
ASCO 2025: Postoperative ctDNA in Pancreatic & Oral Cancer, Desmoid Tumor Therapy ASCO Market Trend Postoperative ctDNA-based MRD predicts recurrence in pancreatic and oral cancers, guiding personalized therapy. Radiotherapy plus bevacizumab shows efficacy in desmoid tumors with ATR mutation as a key predictor.
2025 ASCO: Domestic ADCs, Bispecifics, Trispecifics, Small Molecules ASCO Market Trend Explore the major highlights from ASCO 2025, featuring cutting-edge Chinese innovations in ADCs, bispecific and trispecific antibodies, and small molecule drugs with promising clinical trial results across multiple cancer types.
ASCO 2025: Latest Clinical Advances in Solid Tumor CAR-T Therapies from China and the U.S. ASCO Market Trend CAR-T Explore key updates from ASCO 2025 on solid tumor CAR-T therapies, including clinical trial data from leading Chinese firms and U.S. companies like A2 Bio, showcasing promising safety and efficacy results.
Four Biotechs Face Challenges Amid U.S. COVID-19 Vaccine Funding Cuts FDA WHO Biotech U.S. COVID-19 vaccine biotechs face funding cuts, regulatory changes, and operational challenges. Learn how Vaxart, Novavax, GeoVax, and CastleVax navigate this uncertain landscape impacting future pandemic preparedness.
ASCO 2025: Breakthrough Cancer Trials, Innovative Therapies, and China's Rising Role ASCO Market Trend The 2025 ASCO meeting highlights breakthrough cancer trials, including advances in breast and blood cancers, innovative bispecific antibodies, radiopharmaceuticals, and China’s growing influence in oncology innovation.
TCG Labs' Juri Biosciences Secures $210M Deal for EpimAb’s Prostate Cancer Therapy EpimAb Biotherapeutics Juri Biosciences TCG Labs Soleil’s Juri Biosciences secures up to $210M licensing deal with EpimAb Biotherapeutics for a novel T-cell engager targeting metastatic prostate cancer, advancing innovative multispecific antibody therapy.